Eiki Kikuchi

Also affiliated with Kishokai Medical Corporation

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Response to First-Line Osimertinib Treatment in Non–Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations”.

Response to First-Line Osimertinib Treatment in Non–Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations

Clinical Lung Cancer(2019)10.1016/j.cllc.2019.05.002

N/A

0.165DataRank · unranked

2 citations

Jun Sakakibara-Konishi, Gaku Yamamoto, Hidenori Kitai, Hidenori Mizugaki, Hajime Asahina +3 more

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

UNC Libraries(2020)10.17615/c0ws-ey78

N/A

0DataRank · unranked

7 citations

Julián Carretero, Roderick T. Bronson, James E. Bradner, Charles Y. Lin, Myles Brown +26 more